Abstracts tagged "Scleredema and fibroblasts"

Abstract Number: 2563 • 2013 ACR/ARHP Annual Meeting
Modulating Myofibroblast Transition Of Human Scleroderma Fibroblasts Through Inhibition Of Rho Guanine Nucleotidase-Regulated Gene Transcription
Andrew Haak¹, Pei-Suen Tsou², Dinesh Khanna³, David A. Fox², Scott D. Larsen⁴ and Richard R. Neubig⁵, ¹Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI, ²Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³University of Michigan Health System, Ann Arbor, MI, ⁴Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI
Background/Purpose: Systemic sclerosis (SSc) or scleroderma, like many fibrotic disorders, has no effective therapy. Deposition of collagen and excess extracellular matrix depends on the transition…
Abstract Number: 653 • 2013 ACR/ARHP Annual Meeting
Norepinephrine-Induced IL-6 Regulates Fibrosis In Systemic Sclerosis
Sei-ichiro Motegi, Akihito Uehara, Kazuya Yamada, Akihiko Uchiyama, Sachiko Ogino, Yoko Yokoyama, Yuko Takeuchi and Osamu Ishikawa, Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan
Background/Purpose: Raynaud phenomenon is freaquently observed in patients of systemic sclerosis (SSc) and characterized by episodic vasospasm and ischemia of extremities in response to cold or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].